SynthesisBMC cardiovascular disorders2017
Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials.
Synthesis in BMC cardiovascular disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Evaluating the efficacy of ubiquinol in heart failure patients: a systematic review and meta-analysis.Future cardiology · 2024Pooled it
- Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2022Pooled it
- The Drp1-CoQ10-Coa6-ETC axis represents a therapeutic potential for working memory impairment caused by neuronal mitochondrial dysfunction.Translational neurodegeneration · 2026Article
- A to Z of Health: An Evidence-Based Narrative Review of Multivitamin-Multimineral and Nutraceutical Supplementation.Cureus · 2026Review
- Precision Medicine: Therapeutically Targeting Mitochondrial Alterations in Heart Failure.JACC. Basic to translational science · 2025Review
- Cellular Senescence, Mitochondrial Dysfunction, and Their Link to Cardiovascular Disease.Cells · 2024Review
- Investigating the individual and combined effects of coenzyme Q10 and vitamin C on CLP-induced cardiac injury in rats.Scientific reports · 2024Article
- Advances in Metabolic Remodeling and Intervention Strategies in Heart Failure.Journal of cardiovascular translational research · 2024Review
- Lifestyle and Lipoprotein(a) Levels: Does a Specific Counseling Make Sense?Journal of clinical medicine · 2024Review
- COVID-19 and myocardial injury: Targeting elevated biomarkers for potential novel therapies.Clinics (Sao Paulo, Brazil) · 2024Article
- Coenzyme Q10 Supplementation in Reducing Inflammation: An Umbrella Review.Journal of chiropractic medicine · 2023Review
- Driving force of deteriorated cellular environment in heart failure: Metabolic remodeling.Clinics (Sao Paulo, Brazil) · 2023Review
- Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure.International journal of molecular sciences · 2022Review
- H-FABP Levels and Psycho-Emotional Improvement of CABG Patients during Cardiac Rehabilitation.Journal of cardiovascular development and disease · 2022Article
- Effects of Coenzyme QAntioxidants (Basel, Switzerland) · 2022Article
- Heart Failure-Do We Need New Drugs or Have Them Already? A Case of Coenzyme Q10.Journal of cardiovascular development and disease · 2022Review
- Review
- Mitochondrial Dysfunction and Cardiovascular Disease: Pathophysiology and Emerging Therapies.Oxidative medicine and cellular longevity · 2022Review
- Effect of E-OJ-01 on Left Ventricular Ejection Fraction and Myocardial Oxygen Consumption: A Randomized, Double-Blind, Placebo-Controlled Study.Journal of multidisciplinary healthcare · 2022Article
- The Instability of the Lipid-Soluble Antioxidant Ubiquinol: Part 3-Misleading Marketing Claims.Integrative medicine (Encinitas, Calif.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe therapeutic efficacy of coenzyme Q10 on patients with cardiac failure remains controversial. We pooled previous clinical studies to re-evaluate the efficacy of coenzyme Q10 in patients with cardiac failure.
methodsWe searched PubMed, Cochrane Library, EMBASE, and Clinical Trials.gov databases for controlled trials. The endpoints were death, left heart ejection fraction, exercise capacity, and New York Heart Association (NYHA) cardiac function classification after treatment. The pooled risk ratios (RRs) and standardized mean difference (SMD) were used to assess the efficacy of coenzyme Q10.
resultsA total of 14 RCTs with 2149 patients met the inclusion criteria and were included in the analysis. Coenzyme Q10 decreased the mortality compared with placebo (RR = 0.69; 95% CI = 0.50-0.95; P = 0.02; I
conclusionPatients with heart failure who used coenzyme Q10 had lower mortality and a higher exercise capacity improvement than the placebo-treated patients with heart failure. No significant differences between the efficacy of the administration of coenzyme Q10 and placebo in the endpoints of left heart ejection fraction and NYHA classification were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.